A1AA Logo

Home
Mission Statement
What is Alpha-1
Need Help Now !
Informational Resources
  • Support
  • Medicine Support
  • Personal Advocacy
  • Education
  • Public Policy
  • Alpha-1 Vets
    Health Tips
    FAQs
    Caregivers
    Membership
    Management Team
    Press Room
    Feedback and Comment
    Our Supporters and Links
    Alpha-1 Advocacy Summary

    Won't you sign up for membership? Simply click HERE
    Joining is free, easy and private.

    to sign up and become a member of our growing community of committed individuals striving to be well informed and educated about Alpha 1.

    Read our Privacy Policy and be assured we are here to help. Let us know what we can do for YOU!
    Baxter
    Talecris
    Aventis
    Accredo Therapeutics
    Coram
    Caring Voice Coalition
    Alpha2alpha
    Testing for AAT Deficiency
    Simply click HERE
    Alpha One International Registry
    provides AAT Deficiency Testing. This AAT Deficiency Testing is a
    COMPLETE CONFIDENCIAL TESTING SERVICE
    and WITHOUT COST TO YOU.
    This testing will include measuring the CONCENTRATION of AAT in your blood, determining the TYPE of ATT in your blood and (where appropriate) determining your AAT genotype by testing the DNA in your blood; State of the art, full-spectrum Alpha-1 Testing .

    Please read the detail at: AAT Deficiency Detection Center
    MedWatch

    The FDA Safety Information and Adverse Event Reporting Program


    Medwatch Alert for Lung Transplant Recipients


    FDA and Roche notified healthcare professionals of the findings of an active comparator study of Valcyte and ganciclovir in heart, liver, kidney, and kidney-pancreas transplant patients at high risk for CMV disease. Based on those findings:

    (1) Valcyte is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk,

    (2) Valcyte is not indicated for use in liver transplant patients, and

    (3) The safety and efficacy of Valcyte for the prevention of CMV disease in other solid organ transplant patients, such as lung transplant patients, have not been established.

    Read the 2003 MedWatch safety summary, including a link to the "Dear Healthcare Professional" letter, at:

    http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#valcyte


    Lking for More Information... Need Help Now! Click Here

    Return Home | Return to Education Resources | Return to Informational Resources


    Alpha-1 Advocacy Alliance, PO Box 202, 103 Rapidan Church Lane, Wolftown, VA 22748
    Telephone: 540-948-6777 or 1-866-FOR-A1AA   (1-866-367-2122) Fax # 540-948-6763

    Copyright © 2006 Alpha-1 Advocacy Alliance, All Rights Reserved

    Home | Disclaimer | Privacy Policy